What is Citius Oncology, Inc.'s cash ratio?

Citius Oncology, Inc. (CTOR) reported cash ratio of 0× in Q1 2026.

What is the long-term trend for Citius Oncology, Inc.'s cash ratio?

Over 3 years (2022 to 2025), Citius Oncology, Inc.'s cash ratio has grown at a -56.1% compound annual growth rate (CAGR), from 0.9× to 0.1×.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

Citius Oncology, Inc. CTOR Cash ratio

Cash ratio at other companies

Merck & Co.MRK

0.2×-0.1×

Delcath SystemsDCTH

3.9×+1.4×

Iovance Biotherapeutics, Inc.IOVA

1.5×+0.1×

Cullinan Therapeutics, Inc.CGEM

2.1×-0.7×

ImmunomeIMNM

21.3×+12.9×

Arcus BiosciencesRCUS

1×0.0×

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Calculated from Citius Oncology, Inc.’s reported figures.

cash and equivalents/total current liabilities=0×

Based on the most recent quarter.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s cash ratio?: Citius Oncology, Inc. (CTOR) reported cash ratio of 0× in Q1 2026.
What is the long-term trend for Citius Oncology, Inc.'s cash ratio?: Over 3 years (2022 to 2025), Citius Oncology, Inc.'s cash ratio has grown at a -56.1% compound annual growth rate (CAGR), from 0.9× to 0.1×.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.